Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca Invests $200 Million For Manufacturing Plant In China Medical City

This article was originally published in PharmAsia News

Executive Summary

AstraZeneca PLC has announced a plan to invest $200 million to build a new manufacturing plant inside Taizhou, Jiangsu-based China Medical City

You may also be interested in...



Boehringer Ingelheim To Break Into Biologics Contract Manufacturing Market In China

Reporting 32% growth in China for 2012, BI will be the first Big Pharma to enter the biologics contract manufacturing space in the country.

With A New CEO, Will AstraZeneca Change Its Approach In Emerging Markets?

Roche’s surging growth in China could hint at what’s coming to AstraZeneca in emerging markets as Pascal Soriot, Roche’s head of pharmaceuticals, takes over at AZ.

AstraZeneca Hints At Acquisitions, Merck And Novo Nordisk React To China Cuts – Emerging Market Earnings Roundup (Part 3)

AstraZeneca plans to enhance capacity in emerging markets while cutting jobs and consolidating operations. Merck sees strong volume growth in China, and Novo Nordisk reports a slow quarterly sales growth in the Chinese human insulin market.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC076395

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel